<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006239</url>
  </required_header>
  <id_info>
    <org_study_id>J9879 CDR0000068164</org_study_id>
    <secondary_id>R01CA067803</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J9879</secondary_id>
    <secondary_id>JHOC-99072306</secondary_id>
    <secondary_id>NCI-T98-0068</secondary_id>
    <nct_id>NCT00006239</nct_id>
  </id_info>
  <brief_title>Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal&#xD;
      white blood cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining phenylbutyrate and tretinoin&#xD;
      in treating patients who have hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and toxicity of phenylbutyrate and tretinoin in patients with&#xD;
           myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.&#xD;
&#xD;
        -  Determine the pharmacokinetic interaction of this regimen in these patients.&#xD;
&#xD;
        -  Determine any potential therapeutic activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of tretinoin.&#xD;
&#xD;
      Patients receive phenylbutyrate IV continuously on days 1-7 of weeks 1, 5, 7, 9, 11, 13, 15,&#xD;
      17, and 19. Patients also receive oral tretinoin three times daily on days 1-7 of weeks 3, 5,&#xD;
      7, 9, 11, 13, 15, 17, and 19. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of tretinoin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6&#xD;
      patients experience dose limiting toxicities.&#xD;
&#xD;
      An additional cohort of 6 patients is accrued at the MTD. These patients receive&#xD;
      phenylbutyrate IV continuously on days 1-3 of weeks 1 and 3-18. These patients also receive&#xD;
      oral tretinoin three times daily on days 1-3 of weeks 2-18. Treatment continues in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium phenylbutyrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed myelodysplastic syndrome (MDS)&#xD;
&#xD;
               -  Refractory anemia&#xD;
&#xD;
               -  Primary refractory leukopenia or thrombocytopenia with morphologic features of&#xD;
                  MDS&#xD;
&#xD;
               -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
               -  Refractory anemia with ringed sideroblasts&#xD;
&#xD;
               -  RAEB in transformation&#xD;
&#xD;
               -  Must have excess blasts or be hematopoietically compromised, defined as one of&#xD;
                  the following:&#xD;
&#xD;
                    -  RBC transfusion dependent&#xD;
&#xD;
                    -  Granulocyte count less than 1,000/mm^3&#xD;
&#xD;
                    -  Platelet count less than 50,000/mm^3 OR&#xD;
&#xD;
          -  Diagnosis of chronic myelomonocytic leukemia&#xD;
&#xD;
               -  Hematopoietically compromised (as defined above) OR&#xD;
&#xD;
               -  Excess blasts OR&#xD;
&#xD;
               -  Evaluable disease related symptomatology (organomegaly or leukemia cutis) OR&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia&#xD;
&#xD;
               -  WBC less than 20,000/mm^3 and stable for at least 2 weeks&#xD;
&#xD;
               -  Unlikely to require cytotoxic therapy during study&#xD;
&#xD;
          -  No CNS or pulmonary leukostasis or CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (transfusion allowed)&#xD;
&#xD;
          -  No disseminated intravascular coagulation&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL (unless due to hemolysis or Gilbert's syndrome)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 2 weeks prior, during, and for 3&#xD;
             months after study&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy, including hematopoietic growth factors,&#xD;
             and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks (1 month for MDS patients) since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven D. Gore, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

